In a decision Friday, Judge Swain largely denied a summary judgment motion in a shareholder class action arising from allegations that Pfizer concealed the risks of two drugs, Celebrex and Bextra.  She rejected the defendants’ argument that the case “concern[ed] merely a ‘good-faith disagreement about the proper interpretation of scientific data” because “the record is replete with evidence that Defendants recognized that Celebrex and Bextra had associated cardiovascular risks, that such risks would be considered material by investors, and that Defendants nonetheless misrepresented and actively concealed these risks.”